Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

Digestive Surgery

Volumn 23, Issue 1-2, 2006, Pages 74-79

  Bloomston, Mark ^a   Bhardwaj, Atul ^a   Ellison, E Christopher ^a   Frankel, Wendy L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b E401 Doan Hall ^*  (United States)

Author keywords

Epidermal growth factor receptor; Pancreatic adenocarcinoma; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TISSUE SECTION; TUMOR CELL; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 33746820175     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093497     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78(suppl):580-591.
3. Schneider G, Lersch C, Schmid RM: Pancreatic carcinogenesis. Clinical implications (in German). Chirurg 2003;74:165-170.
4. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
5. Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song MM, Dong M, Tamura K: Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997;17:3841-3847.
6. Kuniyasu H, Abbruzzese JL, Cleary KR, Fidler IJ: Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol 2001;19:681-685.
7. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H: Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003;11:305-309.
8. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-569.
9. Xiong HQ, Abbruzzese JL: Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002;29(suppl 14):31-37.
10. Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP: Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002;54:1180-1193.
11. Huang ZQ, Buchsbaum DJ, Raisch KP, Bonner JA, Bland KI, Vickers SM: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 2003;111:274-283.
12. Grunwald V, Hidalgo M: Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol 2003;532:235-246.
13. Durkin AJ, Bloomston PM, Rosemurgy AS, Giarelli N, Cojita D, Yeatman TJ, Zervos EE: Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 2003;186:431-436.
14. Kloppel G, Hruban RH, Longnecker DS, et al: Ductal adenocarcinoma of the pancreas; in Hamilton SR, Aaltonen LA (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. Lyon, IARC Press, 2000, pp 221-230.
15. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
16. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-234.
17. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L: The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-978.
18. Gusterson B, Cowley G, Smith JA, Ozanne B: Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 1984;8:649-658.
19. Werner MH, Nanney LB, Stoscheck CM, King LE: Localization of immunoreactive epidermal growth factor receptors in human nervous system. J Histochem Cytochem 1988;36:81-86.
20. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT: Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998;18:4613-4619.
21. 1 in human pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2002;1:620-623.
22. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.
23. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-3669.
24. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1:511-529.
25. Mandal M, Adam L, Mendelsohn J, Kumar R: Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998;17:999-1007.
26. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-1905.
27. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-1333.
28. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-916.
29. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-708.
30. AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
31. Yamanaka Y: The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi 1992;59:51-61.
32. Gansauge F, Gansauge S, Schmidt E, Muller J, Beger HG: Prognostic significance of molecular alterations in human pancreatic carcinoma - an immunohistological study. Langenbecks Arch Surg 1998;383:152-155.
33. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K, Mochizuki H: The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8.